The limited volume of blood collected from the Umbilical Cord substantially limits the ability to fully exploit its potential.

Currently, the average volume of blood collected restricts the therapeutic use of Cord Blood Stem Cells (CBSCs) to patients weighing an average of only about 27kg (57 lbs), which eliminates the majority of adult patients.

There is a need for a simple, reproducible, low-cost – fully sterile – not contaminated method to increase the quality and quantity of Cord Blood collected and the number of Stem Cells extracted.

The SituGen Solution

SituGen has developed the SituGen novel device for effective, reproducible and cost-effective – fully sterile – method to increase the quality of Cord Blood collected and the number of Stem Cells extracted.

SituGen’s solution is a disposable comprehensive, all-inclusive kit for CBSC collection, designed to solve the problem of blood quantity and maximize the volume of UCB and the number and quality of Stem Cells extracted.

The Situgen novel device is needle-free, relieving the “bottleneck” affect created due to a needle.

The SituGen device is fully disinfected and sterilized according to the requirements for all blood collection devices.

Advantages/Features

First and only device capable of extracting sufficient quantities of Stem Cells for transplantation in most adult patients

Clinical trials have been conducted at one of Israel's major Medical Centers and the device was launched in Israel in 2009.

Patent applications were filed covering the apparatus and method for collecting human cord blood from the placenta and the umbilical cord. The regulatory process (FDA and CE) has been initiated and is expected to be completed soon.

The SituGen device is expected to be available for international marketing during 2018.